SCHEMBL3006352

SCHEMBL3006352

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.49
MAPT P10636 7/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP1A1 P04798 2/20 0.42
CYP1B1 Q16678 2/20 0.42
LMNA P02545 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
RAB9A P51151 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
REV1 Q9UBZ9 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NPC1 O15118 4/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
ATM Q13315 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009052 0.93 REV1 (0.47) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3006038 0.92 AR (0.47) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3014441 0.91 AR (0.48) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3018798 0.90 AR (0.48) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3007408 0.90 AR (0.49) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3016181 0.89 AR (0.58) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3020219 0.89 AR (0.52) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3005440 0.88 AR (0.46) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3016975 0.88 SMN1; SMN2 (0.54) ARMAPTUSP2RECQLHSD17B10
SCHEMBL3006375 0.88 AR (0.49) ARMAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.